Combination Therapy
for Joint Pain Relief

Patented Technology Designed
to Address Significant Unmet
Medical Needs

Single Injection Combining
Two Proven Therapies


July 28, 2015
Carbylan Therapeutics Schedules Second Quarter 2015 Financial Results

July 15, 2015
Carbylan Therapeutics Provides Timeline Update for Phase 3 Clinical Program

July 7, 2015
Carbylan Therapeutics Appoints Dr. Prem Ramiya Vice President, Pharmaceutical Development & Supply Chain

June 8, 2015
Carbylan Therapeutics to Present at the JMP Securities 2015 Life Sciences Conference

June 8, 2015
Carbylan Therapeutics Completes Enrollment of Phase 3 Pivotal Trial for Hydros-TA

April 14, 2015
Carbylan Therapeutics, Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

April 8, 2015
Carbylan Therapeutics, Inc. Announces Pricing of Initial Public Offering

December 30, 2014
Carbylan Therapeutics Expands Board of Directors with Three Appointments

July 25, 2011
Carbylan BioSurgery Announces Positive Clinical Trial Results for Hydros-TA in Patients with Pain from Knee Osteoarthritis

January 5, 2011
BioSurgery Completes Enrollment in Key Clinical Feasibility Study of Hydros and Hydros-TA in Patients with Pain from Knee Osteoarthritis; Core Patent Issued

November 26, 2007
Announces $20 Million Series B Financing

Carbylan Therapeutics Technology

Carbylan Therapeutics technology includes drug/device combination products under development based on novel, chemically engineered polymer systems incorporating hyaluronic acid, a well-known polysaccharide widely present in the human body.

Learn More